Novavax (NVAX) Profit After Tax (2016 - 2025)
Historic Profit After Tax for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to -$202.4 million.
- Novavax's Profit After Tax fell 6684.17% to -$202.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $341.7 million, marking a year-over-year increase of 21996.99%. This contributed to the annual value of -$187.5 million for FY2024, which is 6560.02% up from last year.
- According to the latest figures from Q3 2025, Novavax's Profit After Tax is -$202.4 million, which was down 6684.17% from $106.5 million recorded in Q2 2025.
- Novavax's Profit After Tax's 5-year high stood at $518.6 million during Q1 2025, with a 5-year trough of -$846.3 million in Q4 2021.
- Its 5-year average for Profit After Tax is -$142.7 million, with a median of -$168.6 million in 2022.
- Its Profit After Tax has fluctuated over the past 5 years, first plummeted by 191082.7% in 2021, then soared by 45150.53% in 2025.
- Over the past 5 years, Novavax's Profit After Tax (Quarter) stood at -$846.3 million in 2021, then skyrocketed by 78.46% to -$182.2 million in 2022, then increased by 2.12% to -$178.4 million in 2023, then skyrocketed by 54.58% to -$81.0 million in 2024, then crashed by 149.76% to -$202.4 million in 2025.
- Its last three reported values are -$202.4 million in Q3 2025, $106.5 million for Q2 2025, and $518.6 million during Q1 2025.